3月10日 - ** 疗法开发商 Trevi Therapeutics TRVI.O 股价盘前上涨 21.9% 至 5.24 美元
** 该公司称其疗法Haduvio在一项针对慢性咳嗽患者的中期试验中达到了 (link)。
** 该疗法在统计学上显著降低了 24 小时的咳嗽频率
** 目前，美国还没有批准用于治疗无明确病因的阵发性咳嗽或在治疗基础疾病后仍持续 咳嗽的治疗方法
** 葛兰素史克（GSK）GSK.L正在开发一种慢性咳嗽治疗药物，默克（Merck）也有一种治疗这种疾病的实验性药物，但该药物在过去曾两次遭到 (link) FDA 的拒绝。
** 截至上次收盘，TRVI 在过去 12 个月中上涨了 45.8
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.